) and the incidence is increasing. The age-standardised incidence rates in Scotland for the most recent years available 1988-90 are 2.3 per 100 000 for NSGCT and 2.9 per 100 000 for seminoma, both having risen from 1.8 per 100 000 for (Sharp et al., 1993b) . Effective chemotherapy has transformed NSGCT from what was invariably a fatal disease, once it had metastasised, to one which is usually curable (Ellis and Sikora, 1987) . Similarly, the majority of patients with seminoma are now curable with radiotherapy or chemotherapy (Pizzocaro, 1989) . For the whole of Scotland 5 year survival rates of 85.0% and 94.5% have been reported for NSGCT and seminoma, respectively, for the period 1983 -1987 (Sharp et al., 1993b .
Simniauy Details of 1123 patients registered in Scotland between 1983 and 1990 for testicular cancer under the Scottish Cancer Registration Scheme were obtained and compared with registrations within the five Scottish oncology centres. Some registration discrepancies were identified. Twenty-eight cancer registrations (2.5%) were coded to the wrong site. 29 patients seen at oncology centres had no cancer registration and 14 cancer registrations had the wrong histology. Five hundred and twenty-seven patients with testicular nonseminomatous germ cell tumours (NSGCT) and 567 with testicular seminoma were identified. Referral rates to specialist oncology centres for testicular germ cell tumours were measured by period and health board area of residence. For the whole study period 92% of NSGCT and 93% of seminoma patients were referred to specialist centres (Sharp et al., 1993a ) and the incidence is increasing. The age-standardised incidence rates in Scotland for the most recent years available 1988-90 are 2.3 per 100 000 for NSGCT and 2.9 per 100 000 for seminoma, both having risen from 1.8 per 100 000 for (Sharp et al., 1993b) . Effective chemotherapy has transformed NSGCT from what was invariably a fatal disease, once it had metastasised, to one which is usually curable (Ellis and Sikora, 1987) . Similarly, the majority of patients with seminoma are now curable with radiotherapy or chemotherapy (Pizzocaro, 1989) . For the whole of Scotland 5 year survival rates of 85.0% and 94.5% have been reported for NSGCT and seminoma, respectively, for the period 1983 -1987 (Sharp et al., 1993b .
Cure rates may be related to the ability to give effective treatment (Stiller, 1994) , and for NSGCT in the West of Scotland it has been suggested that results are better when there is a particular expertise in the treatment of the disease, with centres seeing more patients performing better (Harding, 1993) . Given this background of increasing incidence and the suggestion that cure rates may vary according to the expertise available, a study on referral of testicular NSGCT and seminoma patients to specialist centres within Scotland has been performed. This study was a precursor to a national audit examining treatment policies, survival and reasons for mortality in patients with NSGCr. Results from this audit are reported in the accompanying papers (Howard et al., 1995a,b for the period 1 January 1983 to 31 December 1990. These cancer registrations were then compared with registrations at the five Scottish oncology centres. A referred case was defined as an oncology centre registration if they had been seen at the centre, or by a specialist associated with the centre.
To perform the comparison oncology centres provided either computer listings of testis cancer cases, or allowed their patient registers and casenotes to be examined. In this way study groups were identified and referral rates to specialist centres measured. For NSGCT only, casenotes for two sub-groups, all new cases in 1989 and all deaths amongst new registrations between 1988 and 1990, were examined more closely as these were the patients for the accompanying audits (Howard et at., 1995a,b) .
For the area of residence analysis the numbers in some health boards of residence at diagnosis of cancer were small so were grouped crudely according to population density. A priori the following groupings were defined (1) 1983 and 1990. Comparison with registrations at specialist oncology centres and review of casenotes showed that of these, 28 were inappropriately registered. A further 14 cases had been coded to the wrong histological group and were recoded to the appropriate group. Conversely 29 cases were recorded at oncology centres, but not included amongst cancer registrations. Thus 527 cases of NSGCT and 567 cases of seminoma, were identified and included in the study group. 
Discsin
The source data for this study were Scottish cancer registra--tions and oncology centre registrations. A total of 28 out of 1123 (2.5% ) of cancer registrations were inappropriately registered as testicular cancer. All diagnoses of patients treated at oncology centres were confirmed or amended, but 76 non-referrals treated in hospitals throughout Scotland not required for the casenote reviews reported in the accompanying papers (Howard et al., 1995a,b) did not have their diagnosis validated. Even allowing for some non-referrals not being testis cancer the percentage of site coding errors compares favourably with the rate reported in a recent study of accuracy of Scottish cancer registrations. In the accuracy study 5.4% of a random sample of all 1990 registrations had been coded to the wrong site (Brewster et al., 1994) .
Twenty-nine cases at oncology centres had never been registered as cancer registrations and a further 14 cases had been allocated the wrong histology. The main reasons for the missed cancer registrations or changes to histology were updating of diagnoses or histology, and 'non-standard' referral to hospital (e.g. from prison or a private hospital).
Inclusion of information from the two casenote NSGCT reviews detailed in the methods section should not have affected consistency of data quality between tumour types to a notable extent. The estimated increase in NSGCT referral rate arising from the casenote reviews was 2%. More important for this study than data quality consistency is the presence of underregistration at oncology centres which suggests overall referral rates in this paper are underestimates.
It has been suggested referral to specialist centres conveys an advantage in outcome (Harding et al., 1993; Stiller, 1994 This audit suggests that at least 92% of NSGCT and 93% of seminoma patients are referred to specialist centres for treatment, that referral does not depend on where patients live and rates reported are thought to be underestimates. This is an important finding considering reports (Harding et al., 1993; Stiller, 1994) which suggest therapy is better in specialist oncology centres or where treatment is centralised. The following papers examine survival and audit therapy within the five Scottish oncology centres (Howard et al., 1995a,b) .
